Arg389Gly-β1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol-Reference-Cited by-同舟云学术

Arg389Gly-β1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol

Published:2007-11 Issue:11 Volume:17 Page:941-949
ISSN:1744-6872
Container-title:Pharmacogenetics and Genomics
language:en
Short-container-title:

Author:

Chen Lu,Meyers Deborah,Javorsky George,Burstow Darryl,Lolekha Pakorn,Lucas Margaret,Semmler Annalese B.T.,Savarimuthu Santiyagu M.,Fong Kwun M.,Yang Ian A.,Atherton John,Galbraith Andrew J.,Parsonage William A.,Molenaar Peter

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Genetics (clinical),Genetics,Molecular Biology,Molecular Medicine,General Pharmacology, Toxicology and Pharmaceutics

Reference39 articles.

1. β-Adrenergic receptor blockade in chronic heart failure;Bristow;Circulation,2000

2. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease.;Lancet,1997

3. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF);Lancet,1999

4. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial;Lancet,1999

5. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study;Circulation,2000

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pediatric Beta Blocker Therapy: A Comprehensive Review of Development and Genetic Variation to Guide Precision-Based Therapy in Children, Adolescents, and Young Adults;Genes;2024-03-20

2. Roles of β-adrenoceptor Subtypes and Therapeutics in Human Cardiovascular Disease: Heart Failure, Tachyarrhythmias and Other Cardiovascular Disorders;Handbook of Experimental Pharmacology;2024

3. Potential of β2AR for added benefit in treating heart failure through a better understanding of signaling;Current Opinion in Physiology;2023-12

4. Pharmacogenomics of Cardiovascular Diseases: The Path to Precision Therapy;Pharmacogenomics and Pharmacogenetics in Drug Therapy [Working Title];2023-10-14

5. Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases;Bulletin of Siberian Medicine;2023-01-20